Core Viewpoint - Shandong Zhongnong United Biotechnology Co., Ltd. (referred to as "Zhongnong United") announced an organizational restructuring aimed at optimizing management systems and improving operational efficiency to align with strategic development plans and business needs [1][2]. Group 1: Organizational Restructuring - The board of directors approved the organizational restructuring proposal during the 16th meeting of the fourth board on October 28, 2025 [1]. - The restructuring is described as an internal management optimization that will not significantly impact production and operational activities, indicating it is a normal internal management measure [1][2]. - The adjustments are based on strategic development planning and business expansion needs, focusing on streamlining internal management processes and resource allocation to enhance decision-making efficiency and organizational responsiveness [1][2]. Group 2: Strategic Development - Zhongnong United emphasizes that the restructuring is a crucial step in improving governance structures, which is expected to lay a solid foundation for future business development [2]. - The optimized organizational structure is believed to better position the company to focus on core business areas and enhance market competitiveness [1][2].

证券代码：003042 证券简称：中农联合 公告编号：2025-037 山东中农联合生物科技股份有限公司 关于调整公司组织架构的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 一、公司组织架构调整情况 股东会 董事会秘书 董事会 战略委员会 总经理 审计委员会 提名委员会 薪酬与考核委员会 运 营 管 理 部 采 购 管 理 部 研 发 中 心 财 务 管 理 部 （ 党 委 办 公 室 ） 人 力 资 源 部 纪 检 监 察 部 销 售 部 市 场 部 证 券 投 资 部 办 公 室 （ 合 规 管 理 部 ） 审 计 部 本次组织架构调整是对公司内部管理机构的调整，不会对公司生产经营活动 产生重大影响。 三、备查文件 1、公司第四届董事会第十六次会议决议。 特此公告。 山东中农联合生物科技股份有限公司 董事会 山东中农联合生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第四届董事会第十六次会议，审议通过了《关于调整公司组织架构的 议案》。为进一步优化管理体系，提高运营效率，公司根据战略发展规划及业务 发展需要，对组织 ...

Group 1 - Company Zhongnong United reported a revenue of approximately 1.508 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.21% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 44.79 million yuan [1] - The basic earnings per share showed a loss of 0.31 yuan [1] Group 2 - As of the report, the market capitalization of Zhongnong United is 2.5 billion yuan [2]

证券代码：003042 证券简称：中农联合 公告编号：2025-035 山东中农联合生物科技股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 一、董事会召开情况 山东中农联合生物科技股份有限公司（以下简称"公司"）第四届董事会第 十六次会议于 2025 年 10 月 28 日在公司会议室以现场结合通讯方式召开。会议 通知已于 2025 年 10 月 18 日通过邮件及专人送达的方式通知到各位董事。本次 会议应出席董事 9 名，实际出席董事 9 名。本次会议由董事长许辉先生主持，高 管列席会议。会议召开符合有关法律法规和《公司章程》的规定，会议合法有效。 2.公司第四届董事会审计委员会 2025 年第四次会议决议。 特此公告。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》。 具体内容详见同日刊载于巨潮资讯网（www.cninfo.com.cn）及《上海证券 报》《证券时报》《中国证券报》《证券日报》的《2025 年第三季度报告》。 本议案已经公司董事会审计委员会审议通过，同意将 ...

Financial Performance - The company's revenue for Q3 2025 was ¥443,983,908.42, representing a decrease of 17.11% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥48,002,862.88, a decline of 104.73% year-on-year[5]. - The basic earnings per share were -¥0.34, down 112.50% from the previous year[5]. - Total operating revenue for the current period was CNY 1,508,162,637.59, a decrease of 1% from CNY 1,526,625,935.73 in the previous period[19]. - Net profit for the current period was a loss of CNY 44,793,158.74, an improvement from a loss of CNY 56,025,191.01 in the previous period[20]. - Basic and diluted earnings per share were both CNY -0.31, compared to CNY -0.39 in the previous period[21]. - Other comprehensive income after tax was a loss of CNY 82,334.26, compared to a loss of CNY 94,267.43 in the previous period[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,905,447,289.10, a decrease of 0.72% from the end of the previous year[5]. - Total assets and equity amounted to CNY 3,905,447,289.10, a slight decrease from CNY 3,933,966,777.06[18]. - Current liabilities rose to ¥2,198,688,261.42 from ¥1,967,329,997.12, indicating an increase of about 11.7%[17]. - The company's total liabilities increased to ¥2,592,659,034.34 from ¥2,579,014,814.37, showing a marginal increase of about 0.5%[17]. - Non-current liabilities decreased to ¥393,970,772.92 from ¥611,684,817.25, a decline of about 35.6%[17]. - The company reported a total of CNY 1,312,788,254.76 in equity attributable to shareholders, a decrease from CNY 1,354,951,962.69[18]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥89,965,998.51, a decline of 109.13% compared to the previous period[10]. - Cash flow from operating activities showed a net outflow of CNY 89,965,998.51, worsening from a net outflow of CNY 43,019,654.10 in the previous period[21]. - Net cash flow from investing activities was -$188.8 million, a decrease from -$255.4 million year-over-year[22]. - Cash inflow from financing activities totaled $739.8 million, slightly up from $735.9 million in the previous period[22]. - Cash outflow for debt repayment was $570.5 million, compared to $575.1 million last year[22]. - The net increase in cash and cash equivalents was -$172.4 million, improving from -$187.7 million year-over-year[22]. - The ending balance of cash and cash equivalents was $67.8 million, down from $191.1 million in the previous year[22]. Operational Metrics - The company reported an increase in accounts receivable by 34.93%, amounting to ¥424,492,651.91, due to an increase in outstanding receivables[10]. - Accounts receivable increased to ¥424,492,651.91 from ¥314,608,088.67, showing a growth of about 35%[16]. - Inventory decreased slightly to ¥493,757,949.88 from ¥502,126,638.30, a reduction of approximately 1.5%[16]. - Short-term borrowings increased by 50.87% to ¥763,784,026.35, driven by higher working capital needs[10]. - Short-term borrowings increased significantly to ¥763,784,026.35 from ¥506,266,485.07, reflecting a growth of approximately 50.7%[17]. - The company's cash and cash equivalents decreased to ¥236,783,395.83 from ¥425,228,213.20, representing a decline of approximately 44.4%[16]. Strategic Focus - The company is focusing on expanding its market presence and developing new technologies to enhance its product offerings[15]. - Research and development expenses were CNY 43,829,348.44, down from CNY 47,174,877.08 in the previous period, indicating a focus on cost management[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,768[12]. - The company's equity remained stable at ¥142,480,000.00[17]. Audit Status - The company has not audited its third-quarter financial report[23].

证券代码：003042 证券简称：中农联合 公告编号：2025-034 山东中农联合生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更或否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025年10月27日（星期一）14:30 2、网络投票时间： 1、股东出席会议的总体情况 参加本次会议的股东及股东授权代表共86名，代表有表决权的股份数 77,260,150股，占公司有表决权股份总数的54.2253％。 其中：出席现场会议的股东及股东授权代表共计5名，代表有表决权的股份 数74,204,000股，占公司有表决权股份总数的52.0803％。 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年10月27日 9:15-9:25、9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年10月27 日9:15-15:00期间的任意时间。 3、现 ...

北京德恒（济南）律师事务所 关于山东中农联合生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见 地址：山东省济南市高新区舜泰北路 567 号银丰科技公园 2 号楼 邮编：250102 网址：www.dehenglaw.com 电话：（86）531-8166 3606 北京德恒（济南）律师事务所 关于山东中农联合生物科技股份有限公司 2025 年第二次临时股东大会的法律意见 北京德恒（济南）律师事务所 关于山东中农联合生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见 德恒 11G20230108-10 号 致：山东中农联合生物科技股份有限公司 北京德恒（济南）律师事务所（以下简称"本所"）作为山东中农联合生物 科技股份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派张 璐律师、邓娟娟律师（以下简称"本所律师"）出席公司 2025 年第二次临时股 东大会（以下简称"本次股东大会"），依据《中华人民共和国公司法》（以下 简称《公司法》）、《上市公司股东会规则》等现行有效的法律、法规、规范性 文件以及《山东中农联合生物科技股份有限公司章程》（以下简称《公司章程》）、 《山东中 ...

Meeting Information - The company will hold its second extraordinary general meeting of shareholders on October 27, 2025 [1][2] - The meeting will be convened by the company's board of directors and complies with relevant laws and regulations [1][5] - The meeting will take place at the company's conference room located at 9999 Jingshi Road, Lixia District, Jinan City [5][6] Voting Procedures - Shareholders can participate in the meeting either in person or through authorized representatives [4][5] - Online voting will be available through the Shenzhen Stock Exchange system from 9:15 AM to 3:00 PM on the meeting day [2][10] - The record date for shareholders eligible to attend the meeting is October 21, 2025 [5][6] Agenda Items - The meeting will review several proposals that have been approved by the board, including amendments to the company's articles of association and various governance rules [7][22] - Proposals 1.00, 2.00, and 3.00 require a two-thirds majority of the voting rights held by attending shareholders for approval [8] - The voting results for small and medium investors will be counted separately and disclosed [8] Registration and Contact Information - Registration for the meeting will occur on October 22, 2025, with specific times for natural and corporate shareholders [9] - The company has provided contact details for inquiries related to the meeting [9]

Group 1 - The core point of the article is that Zhongnong United (SZ 003042) held its 15th meeting of the fourth board of directors on October 10, 2025, to review the proposal for revising the "Audit Committee Work Rules" [1] - For the first half of 2025, Zhongnong United's revenue composition was 97.8% from the pesticide industry, 2.13% from the chemical industry, and 0.07% from other sources [1] - As of the time of reporting, Zhongnong United's market capitalization was 2.3 billion yuan [1]

山东中农联合生物科技股份有限公司 第一章 总则 第一条 为了规范山东中农联合生物科技股份有限公司（以下简称"公司"） 控股子公司（以下简称"子公司"）的经营管理行为，促进子公司健康发展，优 化公司资源配置，提高子公司的经营积极性和创造性，依照《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》《深圳证券交易所 股票上市规则》（以下简称《上市规则》）、《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》及《山东中农联合生物科技股份有限 公司章程》（以下简称《公司章程》）等有关法律法规和规章制度的规定，结合 公司的实际情况，特制定本制度。 第二条 本制度所称子公司是指根据公司总体战略规划、产业结构调整或业 务发展需要而依法设立、投资的具有独立法人主体资格的公司，包括： （一）公司的全资子公司； （二）公司对某一公司持股比例超过 50%，或者虽然未超过 50%，但是依 据协议或者公司所持股份的表决权能对被持股公司股东会的决议产生重大影响 的，公司对其构成控股。 控股子公司管理制度 第三条 公司与子公司之间是平等的法人关系。公司以其持有的股权份额， 依法对子公司享有资产受益 ...